M embers of the vascular endothelial growth factor (VEGF)-gene family play important roles in vascular biology. 1 It has been shown that several cell types express VEGF-A in atherosclerotic lesions and that expression of VEGF-A increases during atherogenesis. 2, 3 Also, VEGF-D is expressed in normal human arteries and atherosclerotic lesions. 4 VEGF-A has been proposed to have several roles in the arterial wall: it can be protective by increasing the production of nitric oxide and prostacyclin 5 and by lowering LDL toxicity. 6 It has also been shown to mediate antiapoptotic effects in endothelium. 7 Conversely, the capability of VEGF-A to stimulate monocyte/macrophage influx into the vessel wall suggests that it may contribute to atherogenesis. 8 It has recently been shown that VEGF-A and angiogenesis are associated with atherosclerotic lesion formation in apolipoprotein (apo) E-knockout mice and cholesterol-fed rab-See p 1248 bits. 9, 10 To gain a more comprehensive view about the issue, we decided to test the effects of VEGF-A, -B, -C, and -D on atherogenesis in LDL receptor (LDLR)/apoB48-deficient mice. Unlike in apoE-knockout mice, in these mice, most of the cholesterol is carried in apoB100-containing LDL, and the lipoprotein profile more closely resembles that in humans. 11 Also, macrophages in LDLR/apoB48-deficient mice can normally produce and secrete apoE. We chose adenoviral gene transfer as a tool to achieve effective transient systemic gene expression during a few weeks' time, because this approach has already been applied in clinical trials. 1 We also tested the effect of recombinant human (rh) VEGF-A protein to compare this model with the previous results obtained in apoE-knockout mice. It was found that adenovirus-mediated VEGF gene transfers had no effect on atherogenesis in LDLR/apoB48-deficient hypercholesterolemic mice.
Methods

Experimental Animals
LDLR/apoB48-deficient mice 11 (nϭ110) were kept on a Westerntype diet (Teklad Adjusted Calories, consisting of 21% [wt/wt] fat and 0.15% cholesterol without sodium cholate) for 3 months. Mice were put on the diet at the age of 2 months. After 6 weeks on the diet, the mice were injected via tail vein with recombinant E1-partial E3-deleted first-generation adenoviruses (1ϫ10 9 PFU): Ad-VEGF-A, Ad-VEGF-B, Ad-VEGF-C, and Ad-VEGF-D or control AdLacZ. Generation, production, and functionality of the adenoviruses containing cDNAs for human VEGF-A165, -B167, -C (fulllength), and -D (proteolytically ⌬N⌬C-processed form) under the cytomegalovirus promoter have been described previously. 12 One group of mice was treated with rhVEGF-A protein (2 g/kg), and another control group of mice was injected with saline. Each group contained 15 to 20 mice, which were euthanized 6 weeks later. Another group of mice (nϭ36) was kept on the diet for 4 months, transduced similarly with adenoviruses or injected with rhVEGF-A protein or saline, and euthanized 6 weeks later (total time on diet, 22 weeks) to evaluate the effect of gene transfer on more established lesions. Diet and water were provided ad libitum. During the gene transfer, the animals were anesthetized with fentanyl-fluanisone (3.15 and 10 mg/kg)/midazolam (5 mg/kg) subcutaneously and euthanized with carbon dioxide.
All animal experiments were approved by the Experimental Animal Committee of Kuopio University. Blood samples were taken after 12 hours of fasting, and plasma lipid levels were measured with enzymatic kits: cholesterol (Ecoline 25, Merck Diagnostica, CHOD-PAP method) and triglycerides (Ecoline Sϩ, Diagnostic Systems, GPO-PAP method). Circulating hVEGF-A, -B, -C, and -D levels were analyzed from the tail-vein blood samples at various time points after the gene transfer with ELISA (R&D; Quantikine, human VEGF-A and VEGF-D and Zymed ELISA kit for VEGF-C). To measure rhVEGF-B167, a sandwich ELISA was developed. Essentially, microtiter plates were coated with 3 g/mL of anti-human VEGF-B monoclonal antibody (MAB3372, R&D Systems) in 50 L of 100 mmol/L NaHCO 3 overnight at 4°C. Residual binding capacity of the plates was blocked by incubating with 50 L PBS containing 3% BSA for 30 minutes at room temperature. The wells were then incubated overnight at 4°C with 50 L of the diluted plasma samples.
Generally, the samples were analyzed by use of at least 2 different dilutions in duplicate. rhVEGF-B167 protein was used as a standard. 13 After extensive washing with PBST, 50 L of affinitypurified rabbit anti-VEGF-B immunoglobulin at a concentration of 1 g/mL in PBS containing 1% BSA was added to detect antibodybound VEGF-B167 and incubated for 2 hours at room temperature. 14 After extensive washings as above, bound rabbit immunoglobulin was detected by incubating with 50 L of anti-rabbit-IgG conjugated with alkaline phosphatase for 1.5 hours at room temperature using a 1:3000 dilution in 1% BSA-PBS. After extensive washing with PBST, bound enzyme conjugates were quantified and visualized with NPP substrate (Sigma-Aldrich). After the reaction had been stopped with 25 L of 0.5 mol/L NaOH, the absorbance was measured at 405 and 650 nm with an ELISA plate reader. Proteins from the aortas were extracted with T-PER Tissue Protein extraction reagent including Halt protease inhibitors and analyzed with ELISA (R&D; Quantikine, human VEGF-165 and mouse VEGF-164). Total protein contents were assayed with a BCA Protein Assay kit (Pierce).
Quantification of Atherosclerotic Lesions
The arterial tree was perfused with PBS with buffered formalin (10%) and postfixed with 10% formalin for 2 hours. The whole aorta from the arch to the bifurcation was dissected from 8 to 12 mice in each group as described previously. 15 These aortas were opened longitudinally and analyzed for the presence of en face macroscopic lesions with an MCID/M4-image analyzer (Imaging Research). Aortas from the rest of the mice were embedded in paraffin to evaluate cross-sectional lesion areas and cellular composition of the lesions. Complicated lesions were defined by the presence of atheroma and/or cholesterol crystals covered by several layers of cells and/or connective tissues. 15 Cross-sectional lesion areas were quantified as whole lesion areas surrounded by the vascular ring from the aortic sinus level, which is recognized by the presence of 3 valve cusps. The percentage of macrophages of the total lesion areas was also determined from the same sinus level (Analysis program, Media Cybernetics). 15 All analyses were performed blindly without knowledge of the origin of the samples. 
Immunohistochemistry
For immunohistochemical analysis, serial sections (6 m) of the aortic arch were cut and stained with a modified Movat's pentachrome stain 16 or immunostained with the following antibodies: macrophages (mMQ AIA31240, dilution 1:5000, Accurate Chemical and Scientific Corp), oxidation-specific epitopes (MAL-2, dilution 1:1000), 17 smooth muscle cells (␣-actin, clone 1A4, dilution 1:200, Sigma), CD-31 (PECAM, dilution 1:20, BD Pharmingen), and CD-34 (MEC 14.7, dilution 1:20, HyCult Biotechnology BV) as described previously. 15 Briefly, tissue sections were treated with 0.3% hydrogen peroxide to inhibit endogenous peroxidase activity and were incubated first overnight with 10% normal serum of the respective species, followed by 1 hour of incubation with the primary antibodies, the respective biotinylated secondary antibodies, and avidin-biotin complex (Vector Laboratories). The reaction was visualized by use of DAP as a substrate (Sigma). Sections were counterstained with hematoxylin. In liver sections, endogenous avidin-biotin binding activity was blocked by an avidin-biotin blocking kit (Elite Vectastain). Control immunostainings included incubations in which primary antibodies were omitted and incubations in which primary antibodies were replaced with class-and species-matched irrelevant immunoglobulins. 15 Neovascularization areas in liver, aortic wall, and adventitia were screened at low magnification, and the most vascularized areas were analyzed from 5 different fields at ϫ200 magnification at each section. Results were transformed to the number of capillaries per square millimeter and the number of capillaries per section.
Statistical Analysis
Calculations of the en face lesion areas, cross-sectional lesion areas, and areas with neovascularization were performed independently 3 times, and average values are reported. Data are expressed as meanϮSD and were compared between the groups by ANOVA, followed by modified t test (SPSS 7.5, SPSS Inc). A value of PϽ0.05 was considered significant.
Results
Tail-vein injections of adenoviruses led to transgene expression primarily in the liver. 18 Growth factors were secreted into the systemic circulation as detected by ELISA assays. Human VEGF-A, -B, -C, and -D were still detectable in the circulation 4 to 6 weeks after the gene transfer, although the peak expression was achieved 4 days after the gene transfer (Figure 1) . Human VEGF-A protein was detectable only a few minutes after the intravenous injection of rhVEGF-A and was already below the detection limit after 15 minutes (data not shown). Serum levels of the endogenous mouse VEGFs in nontransduced control mice or in mice transduced with LacZ adenovirus were not detectable with the human assays. We also analyzed the levels of human VEGF-A 5 days after the Ad-VEGF-A gene transfer from aortic extracts with ELISA and found that human VEGF-A was present at 4 to 10 times higher concentration than mouse endogenous VEGF-A (451Ϯ290 pg/mg hVEGF-A165, compared with 59Ϯ20 pg/mg mVEGF-A164).
No statistically significant differences were found between the study groups in serum total cholesterol or triglyceride levels, en face atherosclerosis, or atherosclerotic lesion areas measured from histological sections taken from the aortic sinus level (Table and Figure 2 ). Atherosclerotic lesions were rich in macrophage-derived foam cells, and staining patterns were similar in all groups (Figure 3 ). No differences were found in the percentage of lesion macrophages, which varied between 40% and 70% of the lesion areas (Table) . We did not find any differences in the prevalence of complicated lesions. Even if there were more newly formed capillaries in the livers, especially in the VEGF-A and -D-transduced groups, no increased neovascularization was found in the atherosclerotic lesions or in the aortic adventitia ( Figure 4 ).
Discussion
On the basis of recent animal studies, concerns have been raised about the potential proatherogenic effects of the VEGF gene or protein therapies. Celletti et al 9 reported increased atherogenesis in apoE-deficient mice and cholesterol-fed rabbits, and Moulton et al 10 showed that angiogenesis inhibitors can reduce atherogenesis in apoE-deficient mice. Because several members of the VEGF gene family are currently in clinical trials, 1 it is important to clarify potential proatherogenic effects of the members of the VEGF family. We decided to use systemic delivery of adenoviruses encoding VEGF-A, -B, -C, and -D in LDLR/apoB48-deficient mice to gain further insights into the issue. Even though most human trials have used local intracoronary or intramyocardial delivery of VEGF genes or recombinant proteins, systemic delivery is the only feasible nontraumatic approach for gene or recombinant protein delivery in mice. However, we recognize that our results do not exclude the possibility of VEGF-derived harmful effects potentially caused by higher doses or alternative delivery routes.
In this study, we found no evidence that transient expression of the members of the VEGF gene family would cause any proatherogenic changes in mouse aortas. The results are in line with results from recent clinical ND indicates not determined. n of the analyzed samples is shown in parentheses. trials (VIVA Trial, 19 KAT Trial, 20 Euroinject One Trial 21 ) that did not show any evidence of increased atherogenesis in human arteries after systemic delivery of either rhVEGF-A 165 protein or Ad-VEGF-A 165 or VEGF-A 165 plasmid. Even though angiogenesis and atherogenesis share some common denominators, it is important to recognize that atherogenesis is a different process from angiogenesis and that lipids, smooth muscle cell proliferation, and matrix accumulation still play major roles in the development of atherosclerotic lesions. 22, 23 Previous studies were performed predominantly in apoEknockout mice 9,10 by use of systemic delivery of rhVEGF-A 165 . It is important to note that the lipoprotein profile in apoE-knockout mice is very different from that of humans.
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Most of the cholesterol is carried in chylomicron and VLDL particles, 24 and the lack of the ability of macrophages to produce apoE protein has a significant impact on atherogenesis. 25 It is generally accepted that atherogenesis in apoE Ϫ/Ϫ mice is heavily dependent on monocyte-macrophages and hence very susceptible to potential effects of the growth factors on bone marrow. Also, Celletti et al used only thoracic aorta for the evaluation of atherosclerotic lesions. According to our experience, lesions in the thoracic aorta are usually more random and less predictable than elsewhere in the aortic tree. Also, increased levels of VEGF-A in plasma are very difficult to achieve after intraperitoneal or intramuscular injections with rhVEGF proteins. In our study, after the tail-vein injection of the recombinant protein, rhVEGF-A was detectable in the circulation for only a few minutes. Thus, it is likely that at least some of the results published earlier 9,10 may be a result of the special properties of the apoE-knockout mouse as a model for atherogenesis.
We used LDLR/apoB48-deficient mice in which the majority of cholesterol is transported in apoB100-containing lipoproteins (ie, LDL fraction). Also, in these mice, apoE production in macrophages is normal, and the lesion development is not as greatly affected by the inability of macro-phages to secrete apoE. Thus, we believe that LDLR/apoB48knockout mice will represent human atherosclerosis at least equally as well as apoE-knockout mice. According to the results, no major changes in atherogenesis were found in these mice after transient gene transfer of any of the members of the VEGF gene family. Also, no changes were found in angiogenesis in atherosclerotic lesions or aortic adventitia. Our results show that in this mouse model, transient expression of VEGF growth factors, as verified by increased levels of the transduced proteins in peripheral blood and aortas, does not enhance atherogenesis in large arteries.
In conclusion, no evidence of increased atherogenesis was found in LDLR/apoB48-deficient mice after adenovirusmediated systemic gene transfers of VEGF-A, -B, -C, and -D. The results are in line with findings from recent phase II/III clinical trials. 19 -21 The results are also compatible with the vasculoprotective properties of the low levels of VEGF that have been demonstrated in animal studies. 5, 7 It is obvious that the possibility of enhanced atherogenesis should be carefully monitored in forthcoming clinical trials involving VEGF recombinant proteins or genes. However, the present results do not suggest any increased proatherogenic effects of the members of the VEGF gene family when expressed transiently after systemic adenoviral gene transfer. 
